1 week Ago By ABMN Staff
Renaissance Technologies LLC purchased a new stake in Taysha Gene Therapies, Inc. ( NASDAQ:TSHA – Free Report ) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 878,448 shares of the company’s stock, valued at approximately $1,520,000.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Charles Schwab Investment Management Inc. grew its holdings in shares of Taysha Gene Therapies by 2.
5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 474,257 shares of the company’s stock valued at $820,000 after buying an additional 11,390 shares during the last quarter.
Geode Capital Management LLC boosted its stake in Taysha Gene Therapies by 23.7% during the 3rd quarter. Geode Capital Management LLC now owns 3,562,758 shares of the company’s stock valued at $7,163,000 after purchasing an additional 682,273 shares during the last quarter.
Barclays PLC increased its holdings in Taysha Gene Therapies by 356.0% during the 3rd quarter. Barclays PLC now owns 247,280 shares of the company’s stock worth $513,000 after purchasing an additional 193,046 shares in the last quarter.
Vanguard Group Inc. raised its stake in shares of Taysha Gene Therapies by 7.8% in the fourth quarter.
Vanguard Group Inc. now owns 8,906,764 shares of the company’s stock worth $15,409,000 after purchasing an additional 641,305 shares during the last quarter. Finally, JPMorgan Chase & Co.
lifted its holdings in shares of Taysha Gene Therapies by 1.3% in the third quarter. JPMorgan Chase & Co.
now owns 3,001,397 shares of the company’s stock valued at $6,033,000 after purchasing an additional 37,844 shares in the last quarter. Institutional investors own 77.70% of the company’s stock.
Analyst Upgrades and Downgrades Several brokerages recently issued reports on TSHA. Chardan Capital reiterated a “buy” rating and set a $7.00 price target on shares of Taysha Gene Therapies in a report on Wednesday, February 26th.
Needham & Company LLC reiterated a “buy” rating and issued a $6.00 target price on shares of Taysha Gene Therapies in a report on Thursday, April 10th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.
com, the company has a consensus rating of “Buy” and an average target price of $6.63. Taysha Gene Therapies Stock Performance NASDAQ TSHA opened at $1.
76 on Monday. The company has a market capitalization of $360.90 million, a PE ratio of 2.
79 and a beta of 0.96. The company has a debt-to-equity ratio of 0.
48, a quick ratio of 5.51 and a current ratio of 5.51.
Taysha Gene Therapies, Inc. has a 52-week low of $1.05 and a 52-week high of $4.
32. The company has a 50-day simple moving average of $1.55 and a 200 day simple moving average of $1.
80. Taysha Gene Therapies ( NASDAQ:TSHA – Get Free Report ) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.
07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.01.
Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%.
The company had revenue of $2.02 million during the quarter, compared to analyst estimates of $2.05 million.
On average, research analysts predict that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current year.
Taysha Gene Therapies Company Profile ( Free Report ) Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Featured Stories Want to see what other hedge funds are holding TSHA? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Taysha Gene Therapies, Inc. ( NASDAQ:TSHA – Free Report ). Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.
com's FREE daily email newsletter ..
